Li Ning, Yang Bo-yan, Li Jun-ling, Zhu Ji-qing, Zou Bao-hua, Wang Yan-feng, Yu Lei, Yao Xiao-ying
Department of General Medicine, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Email:
Zhonghua Zhong Liu Za Zhi. 2013 Nov;35(11):867-70.
To investigate the clinical characteristics and prognostic factors of leptomeningeal metastases (LM) from solid tumors and to develop better treatment strategies.
The clinical characteristics and follow-up results of 77 cases of leptomeningeal metastases (LM) from solid tumors diagnosed and treated in our hospital from 2002 to 2011 were retrospectively analyzed. Clinical characteristics, treatment methods and overall survival were analyzed using Kaplan-Meier method and Cox regression model.
The median survival time for all the patients was 88 days. KPS score, control of the primary tumor and systemic treatment were correlated with survival time for the patients (P < 0.05 for all). The median survival time of systemic treatment was 150 d and those without systemic treatment (chemotherapy and/or targeted therapy) after LM was 60 d (P = 0.001). Systemic therapy combined with local treatment (radiotherapy to the meninges or intrathecal chemotherapy) further improved the survival time of patients. Multivariate analysis showed that KPS and short-term therapeutic response for the LM were independent prognostic factors (P < 0.05 for both).
KPS and short-term therapeutic response are independent prognostic factores for leptomeningeal metastases from solid tumors. Systemic chemotherapy or targeted therapy can prolong the survival time. Systemic treatment (chemotherapy and/or targeted therapy) combined with radiation therapy or intrathecal injection may further improve the clinical outcomes.
探讨实体瘤软脑膜转移(LM)的临床特征及预后因素,以制定更好的治疗策略。
回顾性分析2002年至2011年在我院诊断和治疗的77例实体瘤软脑膜转移患者的临床特征及随访结果。采用Kaplan-Meier法和Cox回归模型分析临床特征、治疗方法及总生存期。
所有患者的中位生存时间为88天。KPS评分、原发肿瘤的控制情况及全身治疗与患者的生存时间相关(均P < 0.05)。全身治疗的中位生存时间为150天,软脑膜转移后未接受全身治疗(化疗和/或靶向治疗)的患者中位生存时间为60天(P = 0.001)。全身治疗联合局部治疗(脑膜放疗或鞘内化疗)进一步提高了患者的生存时间。多因素分析显示,KPS及软脑膜转移的短期治疗反应是独立的预后因素(均P < 0.05)。
KPS及短期治疗反应是实体瘤软脑膜转移的独立预后因素。全身化疗或靶向治疗可延长生存时间。全身治疗(化疗和/或靶向治疗)联合放疗或鞘内注射可能进一步改善临床结局。